Eye Catching Stocks: Gilead Sciences Inc. (GILD), Halliburton Company (HAL), Morgan Stanley (MS)

Gilead Sciences Inc. (GILD) continued its upward trend with the stock climbing 0.73% or $0.51 to close the day at $70.31 on active trading volume of 10.94M shares, compared to its three month average trading volume of 10.57M. The Foster City California 94404 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -19.16%, compared to the industry which has advanced 0.84% over the same period. With RSI of 48.38, the stock should still continue to rise and get closer to its one year target estimate of $84.27, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Halliburton Company (HAL) fell -2.62% during last trading as the stock lost $-1.46 to finish the day at $54.31 with about 10.91M shares changing hands, compared to its three month average trading volume of 8.14M. The $47.54B market cap company, which fluctuated between $54.26 and $56 during the day, currently situated 88.77% above its 52 week low of $30.84 and -7.6% away from its one year high of $58.78. The RSI of 41.8 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company’s Completion and Production segment offers production enhancement services, including stimulation and sand control services; and cementing services, such as bonding the well, well casing, and casing equipment. It also provides completion tools that offer downhole solutions and services, including well completion products and services, intelligent well completions, liner hanger systems, sand control systems, and service tools; pressure control services comprising coiled tubing, hydraulic workover units, and downhole tools; and pipeline and process services, such as pre-commissioning and maintenance, subsea pipeline, conventional pipeline, and process services. In addition, this segment offers oilfield production and completion chemicals and services; electrical submersible pumps and progressive cavity pumps; and installation, maintenance, repair, and testing services. The company’s Drilling and Evaluation segment provides drilling fluid systems, performance additives, completion fluids, solids control, specialized testing equipment, and waste management services; and drilling systems and services. It also offers wireline and perforating services, including open-hole logging, and cased-hole and slickline services; and drill bits and services comprising roller cone rock bits, fixed cutter bits, hole enlargement, and related downhole tools and services, as well as coring equipment and services. In addition, this segment offers integrated exploration, drilling, and production software, as well as related professional and data management services; testing and subsea services, such as acquisition and analysis of reservoir information and optimization solutions; and oilfield project management and integrated solutions. Halliburton Company was founded in 1919 and is based in Houston, Texas.

Morgan Stanley (MS) saw its value decrease by -0.82% as the stock dropped $-0.38 to finish the day at a closing price of $46.11. The stock was lighter in trading and has fluctuated between $22.68-$46.75 per share for the past year. The shares, which traded within a range of $45.8 to $46.5 during the day, are up by 15.8% in the past three months and up by 53.43% over the past six months. It is currently trading 5.31% above its 20 day moving average and 6.74% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $47.38 a share over the next twelve months. The current relative strength index (RSI) reading is 63.68. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The company’s Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; and corporate lending services, credit products, and investments and research services. Its Wealth Management segment offers various financial services and solutions covering brokerage and investment advisory services, market-making services in fixed income securities, financial and wealth planning services, annuity and insurance products, credit and other lending products, and banking and retirement plan services to individual investors, small-to-medium sized businesses, and institutions. The company’s Investment Management segment provides various investment strategies and products comprising asset management, including equity, fixed income, liquidity, alternatives, and managed futures products. This segment is also involved in merchant banking and real estate investing businesses. Morgan Stanley was founded in 1924 and is headquartered in New York, New York.

 

3 Stocks in Focus: Gilead Sciences Inc. (GILD), General Motors Company (GM), Baxter International Inc. (BAX)

Gilead Sciences Inc. (GILD) fell -0.15% during last trading as the stock lost $-0.1 to finish the day at $67.55 with about 14.91M shares changing hands, compared to its three month average trading volume of 10.34M. The $88.9B market cap company, which fluctuated between $67.33 and $68.67 during the day, currently situated 3.32% above its 52 week low of $65.38 and -33.29% away from its one year high of $103.1. The RSI of 35.55 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

General Motors Company (GM) gained $1.72 to close the day at a new closing price of $37.24, a 4.84% increase in value from its previous closing price that moved the stock 40.72% above its 52 week low of $27.05. A total of 31.23M shares exchanged hands during the day compared with its three month average trading volume of 14.16M. The stock, which fluctuated between $36.67 and $37.4 during the day, currently situated -2.97% below its 52 week high. The stock is down by -0.27% in the past one month and up by 10.65% over the past three months. With a one year target estimate of $38.82 and RSI of 56.83, the stock still has upside potential, making it a hold for now.

General Motors Company designs, builds, and sells cars, trucks, crossovers, and automobile parts worldwide. The company operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. It markets its vehicles primarily under the Buick, Cadillac, Chevrolet, GMC, Holden, Opel, Vauxhall, Baojun, Jiefang, and Wuling brand names. The company also sells cars, trucks, and crossovers to dealers for consumer retail sales, as well as to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers connected safety, security and mobility solutions, and information technology services. The company, through its subsidiary, General Motors Financial Company, Inc., provides automotive financing services. General Motors Company was founded in 1897 and is based in Detroit, Michigan.

Baxter International Inc. (BAX) had a light trading with around 2.74M shares changing hands compared to its three month average trading volume of 3.36M. The stock traded between $48.77 and $49.31 before closing at the price of $48.96 with -0.55% change on the day. The Deerfield Illinois 60015 based company is currently trading 35.07% above its 52 week low of $37.36 and -2.11% below its 52 week high of $50.16. Both the RSI indicator and target price of 69.23 and $52.88 respectively, lead us to believe that it should be put on hold over the coming weeks.

Baxter International Inc. provides a portfolio of renal and hospital products. Its Renal segment provides products and services to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis (HD), home HD, continuous renal replacement therapy, and additional dialysis services. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and by patients at home under physician supervision. Baxter International Inc. offers its products through direct sales force, independent distributors or sales agents, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. The company was founded in 1931 and is headquartered in Deerfield, Illinois.

 

Stocks in Review: Sirius XM Holdings Inc. (SIRI), Regions Financial Corporation (RF), Gilead Sciences Inc. (GILD)

Sirius XM Holdings Inc. (SIRI) traded within a range of $4.69 to $4.74 after opening the day at $4.71. The company has seen its stock increase in value by 6.52% so far this year. The stock was up close to 0.42% on light volume in last trading session and closed at $4.73 per share. After the recent gain, the stock is currently holding -1.66% below its 52 week high of $4.82 and 43.12% above its 12-month low of $3.42. The shares are up by over 10.49% in the last three months, and the RSI indicator value of 59.08 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Sirius XM Holdings Inc. provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, including various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and limited run channels. It also streams music and non-music channels over the Internet; and offer applications to allow consumers to access its Internet radio service on smartphones, tablets, computers, home devices, and other consumer electronic equipment. In addition, the company distributes satellite radios through the sale and lease of new vehicles; and acquires subscribers through the sale and lease of previously owned vehicles with factory-installed satellite radios. Its satellite radio systems include satellites, terrestrial repeaters, and other satellite facilities; studios; and radios. Further, the company provides satellite television services, which offer music channels on the DISH NETWORK satellite television service as a programming package; Travel Link, a suite of data services that include graphical weather, fuel prices, sports schedule and scores, and movie listings; real-time traffic services; and real-time weather services. Additionally, it offers location-based services through two-way wireless connectivity, including safety, security, convenience, maintenance and data services, remote vehicles diagnostics, and stolen or parked vehicle locator services. The company also sells satellite radios directly to consumers through its Website, as well as through national and regional retailers. The company was founded in 1990 and is headquartered in New York, New York. Sirius XM Holdings Inc. is a subsidiary of Liberty Media Corporation.

Regions Financial Corporation (RF) managed to rebound with the stock declining 0% or $0 to close the day at $14.99 on light trading volume of 17.5M shares, compared to its three month average trading volume of 21.13M. The Birmingham Alabama 35203 based company has been outperforming the regional – southeast banks group over the past 52 weeks, with the stock gaining 117.14%, compared to the industry which has advanced 69.74% over the same period. With RSI of 61.49, the stock should still continue to rise and get closer to its one year target estimate of $15.23, making it a hold for now.

Regions Financial Corporation, together with its subsidiaries, provides banking and bank-related services to individual and corporate customers in the United States. Its Corporate Bank segment offers commercial banking services, such as commercial and industrial, commercial real estate, and investor real estate lending, as well as equipment lease financing services. This segment serves corporate, middle market, small business, and commercial real estate developers and investors. The company’s Consumer Bank segment provides consumer banking products and services related to residential first mortgages, home equity lines and loans, small business loans, indirect loans, consumer credit cards, and other consumer loans, as well as the corresponding deposit relationships. Its Wealth Management segment offers wealth management products and services, including credit related products, trust and investment management, asset management, retirement and savings solutions, estate planning, and personal and commercial insurance products to individuals, businesses, governmental institutions, and non-profit entities. The company also provides insurance coverage for various lines of personal and commercial insurance, such as property, vehicle, casualty, life, health, and accident insurance, as well as commercial crop, life, and environmental insurance; and commercial equipment financing products, as well as offers securities, insurance, and advisory services through financial consultants. In addition, it offers securities brokerage, merger and acquisition advisory, trust, and other specialty financing services. As of December 31, 2015, the company operated 1,627 banking offices and 1,962 ATMs in Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Mississippi, Missouri, North Carolina, South Carolina, Tennessee, Texas, and Virginia. Regions Financial Corporation was founded in 1971 and is headquartered in Birmingham, Alabama.

Gilead Sciences Inc. (GILD) gained $0.77 to close the day at a new closing price of $66.36, a 1.17% increase in value from its previous closing price that moved the stock 1.5% above its 52 week low of $65.38. A total of 16.19M shares exchanged hands during the day compared with its three month average trading volume of 10.32M. The stock, which fluctuated between $65.43 and $66.78 during the day, currently situated -34.46% below its 52 week high. The stock is down by -10.04% in the past one month and down by -14.89% over the past three months. With a one year target estimate of $84.27 and RSI of 30.92, the stock still has upside potential, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Stocks Trend Analysis: Bank of America Corporation (BAC), Advanced Micro Devices, Inc. (AMD), Gilead Sciences Inc. (GILD)

Bank of America Corporation (BAC) continued its downward trend with the stock declining -1% or $-0.23 to close the day at $22.67 on light trading volume of 102.2M shares, compared to its three month average trading volume of 120.45M. The Charlotte North Carolina 28255 based company has been outperforming the money center banks group over the past 52 weeks, with the stock gaining 88.73%, compared to the industry which has advanced 25.8% over the same period. With RSI of 46.82, the stock should still continue to rise and get closer to its one year target estimate of $24.79, making it a hold for now.

Bank of America Corporation, through its subsidiaries, provides banking and financial products and services for individual consumers, small and middle-market businesses, institutional investors, large corporations, and governments worldwide. It operates through five segments: Consumer Banking, Global Wealth & Investment Management, Global Banking, Global Markets, and Legacy Assets & Servicing. The Consumer Banking segment offers traditional and money market savings accounts, CDs and IRAs, noninterest- and interest-bearing checking accounts, and investment accounts and products, as well as credit and debit cards, residential mortgages and home equity loans, and direct and indirect loans. This segment provides its products and services through approximately 4,700 financial centers, 16,000 ATMs, call centers, and online and mobile platforms. The Global Wealth & Investment Management segment offers investment management, brokerage, banking, and retirement products, as well as wealth management and customized solutions. The Global Banking segment provides lending products and services, including commercial loans, leases, commitment facilities, trade finance, real estate lending, and asset-based lending; treasury solutions, such as treasury management, foreign exchange, and short-term investing options; working capital management solutions; and debt and equity underwriting and distribution, and merger-related and other advisory services. The Global Markets segment offers market-making, financing, securities clearing, settlement, and custody services, as well as risk management, foreign exchange, fixed-income, and mortgage-related products. The Legacy Assets & Servicing segment engages in mortgage servicing activities related to residential first mortgage and home equity loans; and managing legacy exposures related to mortgage origination, sales, and servicing. Bank of America Corporation was founded in 1874 and is based in Charlotte, North Carolina.

Advanced Micro Devices, Inc. (AMD) grew with the stock adding 2.03% or $0.27 to close at $13.56 on active trading volume of 75.84M compared its three months average trading volume of 56.1M. The Sunnyvale California 94088 based company operating under the Semiconductor – Broad Line industry has been trending up for the last 52 weeks, with the shares price now 613.68% up for the period and up by 19.58% so far this year. With price target of $10.96 and a 649.17% rebound from 52-week low, Advanced Micro Devices, Inc. has plenty of upside potential, making it a hold with a view buy.

Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily include x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products. It provides x86 microprocessors for desktop PCs under the AMD A-Series, AMD E-Series, AMD FX CPU, AMD Athlon CPU and APU, AMD Sempron APU and CPU, and AMD Pro A-Series APU brands; and microprocessors for notebook and 2-in-1s under the AMD A-Series, AMD E-Series, AMD C-Series, AMD Z-Series, AMD FX APU, AMD Phenom, AMD Athlon CPU and APU, AMD Turion, and AMD Sempron APU and CPU brands. The company also offers chipsets with and without integrated graphics features for desktop, notebook PCs, and servers, as well as controller hub-based chipsets for its APUs under the AMD brand; and AMD PRO mobile and desktop processors. In addition, it provides discrete desktop graphics products and discrete GPUs for notebooks under the AMD Radeon brand; professional graphics products under the AMD FirePro brand; and customer-specific solutions based on AMD’s CPU, GPU, and multi-media technologies. Further, the company offers microprocessors for server platforms under the AMD Opteron; embedded processor solutions for interactive digital signage, casino gaming, and medical imaging under the AMD Opteron, AMD Athlon, AMD Sempron, AMD Geode, AMD R-Series, and G-Series brands; and semi-custom SoC products that power the Sony Playstation 4 and Microsoft Xbox One game consoles. Advanced Micro Devices, Inc. sells its products through its direct sales force, independent distributors, and sales representatives. The company serves original equipment manufacturers, original design manufacturers, system builders, and independent distributors. Advanced Micro Devices, Inc. was founded in 1969 and is headquartered in Sunnyvale, California.

Gilead Sciences Inc. (GILD) failed to extend gains with the stock declining -8.61% or $-6.3 to close the day at $66.83 on lower than average trading volume of 51.49M shares, compared to its three month average trading volume of 9.65M. The Foster City California 94404 based company has been underperforming the biotechnology companies by -9.1034% for last three months and its recent losses have pulled the stock down -6.68% YTD, versus the biotechnology industry which is down -4.83% for the same period. The RSI of 30.28 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Momentum Stocks in Focus: Oracle Corporation (ORCL), Cognizant Technology Solutions Corporation (CTSH), Gilead Sciences Inc. (GILD)

Oracle Corporation (ORCL) failed to extend gains with the stock declining -0.82% or $-0.33 to close the day at $40.1 on active trading volume of 7.78M shares, compared to its three month average trading volume of 13.17M. The Redwood City California 94065 based company has been outperforming the application software group over the past 52 weeks, with the stock gaining 14.04%, compared to the industry which has advanced 26.96% over the same period. With RSI of 57.59, the stock should still continue to rise and get closer to its one year target estimate of $43.5, making it a hold for now.

Oracle Corporation develops, manufactures, markets, sells, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide. It offers services in three primary layers of the cloud: Software as a Service, Platform as a Service, and Infrastructure as a Service. The company licenses its Oracle Database software, which enables storage, retrieval, and manipulation of various forms of data; and Oracle Fusion Middleware software to build, deploy, secure, access, and integrate business applications, as well as automate their business processes. It also provides a range of software for mobile computing to address the development needs of businesses; and Java, a software development language. In addition, the company offers application software, such as human capital and talent management, customer experience and customer relationship management, financial management and governance, risk and compliance, procurement, project portfolio management, supply chain management, business analytics and enterprise performance management, and industry-specific application software. Further, it offers hardware systems products, such as Oracle Engineered Systems, servers, storage, networking, industry specific hardware, virtualization software, operating systems, management software, and related hardware services. Additionally, the company offers customers with rights to software product upgrades and maintenance releases, patches released, and Internet access to technical content, as well as Internet and telephone access to technical support personnel. The company also provides consulting services, such as IT strategy alignment, enterprise architecture planning and design, initial product implementation and integration, and ongoing product enhancement and upgrade; customer support services; and education services. Oracle Corporation was founded in 1977 and is headquartered in Redwood City, California.

Cognizant Technology Solutions Corporation (CTSH) grew with the stock adding 0.5% or $0.26 to close at $52.76 on active trading volume of 7.76M compared its three months average trading volume of 6.42M. The Teaneck New Jersey 07666 based company operating under the Business Software & Services industry has been trending down for the last 52 weeks, with the shares price now -9.87% down for the period and down by -5.84% so far this year. With price target of $63.81 and a 16.11% rebound from 52-week low, Cognizant Technology Solutions Corporation has plenty of upside potential, making it a hold with a view buy.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. Its consulting and technology services include IT strategy consulting, program management consulting, operations improvement consulting, strategy consulting, and business consulting services; and application design and development, systems integration, enterprise resource planning, and customer relationship management implementation services. The company also offers enterprise information management services, such as strategic, advisory, and management consulting; enterprise data management; descriptive analytics/business intelligence; strategic corporate performance management; and packaged analytics services, as well as big data services that assist clients in managing and deriving actionable insights. In addition, it provides application testing services; and develops, licenses, implements, and supports proprietary and third-party software products, as well as offers digital technologies services. Further, the company offers outsourcing services, such as application maintenance services; IT infrastructure services; and business process services, including clinical data management, pharmacovigilance, equity research support, commercial operations, and order management. It serves various industries, including banking and insurance; healthcare and life sciences; manufacturing and logistics; retail, travel, and hospitality; consumer goods; communications; information, media, and entertainment; and technology. The company markets and sells services through its professional staff, senior management, and direct sales personnel. Cognizant Technology Solutions Corporation was founded in 1998 and is headquartered in Teaneck, New Jersey.

Gilead Sciences Inc. (GILD) continued its upward trend with the stock climbing 0.07% or $0.05 to close the day at $72.39 on lower than average trading volume of 7.5M shares, compared to its three month average trading volume of 9.69M. The Foster City California 94404 based company has been outperforming the biotechnology companies by 1.4954% for last three months and its recent gains have pushed the stock slightly up 1.09% YTD, versus the biotechnology industry which is down -5.25% for the same period. The RSI of 50.38 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Momentum Stocks in Focus: Gilead Sciences Inc. (GILD), PayPal Holdings, Inc. (PYPL), U.S. Bancorp (USB)

Gilead Sciences Inc. (GILD) failed to extend gains with the stock declining -0.78% or $-0.57 to close the day at $72.25 on light trading volume of 8.75M shares, compared to its three month average trading volume of 9.8M. The Foster City California 94404 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -14.43%, compared to the industry which has advanced 7.3% over the same period. With RSI of 49.39, the stock should still continue to rise and get closer to its one year target estimate of $93.71, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

PayPal Holdings, Inc. (PYPL) grew with the stock adding 0.69% or $0.27 to close at $39.58 on active trading volume of 8.74M compared its three months average trading volume of 7.19M. The San Jose California 95131 based company operating under the Credit Services industry has been trending up for the last 52 weeks, with the shares price now 6.94% up for the period and up by 0.28% so far this year. With price target of $46.65 and a 25.09% rebound from 52-week low, PayPal Holdings, Inc. has plenty of upside potential, making it a hold with a view buy.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants worldwide. It enables businesses of various sizes to accept payments from merchant Websites, mobile devices, and applications, as well as at offline retail locations through a range of payment solutions, including PayPal, PayPal Credit, Braintree, Venmo, and Xoom products. The company’s platform allows customers to pay and get paid, transfer and withdraw funds to their bank accounts, and hold balances in their PayPal accounts in various currencies. PayPal Holdings, Inc. was founded in 1998 and is headquartered in San Jose, California.

U.S. Bancorp (USB) continued its upward trend with the stock climbing 0.19% or $0.1 to close the day at $53.13 on higher than average trading volume of 8.7M shares, compared to its three month average trading volume of 7.53M. The Minneapolis Minnesota 55402 based company has been outperforming the regional – midwest banks companies by 19.9326% for last three months and its recent gains have pushed the stock slightly up 3.43% YTD, versus the regional – midwest banks industry which is down -0.73% for the same period. The RSI of 65.63 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

U.S. Bancorp, a financial services holding company, provides a range of financial services in the United States. It offers depository services, which include checking accounts, savings accounts, and time certificate contracts; and lending services, such as traditional credit products, as well as credit card services, leasing financing, import/export trade, asset-backed lending, agricultural finance, and other products. The company also provides ancillary services, including capital markets, treasury management, and receivable lock-box collection services to corporate customers; and a range of asset management and fiduciary services for individuals, estates, foundations, business corporations, and charitable organizations. In addition, it offers investment and insurance products to the company’s customers principally within its markets, as well as fund administration services to a range of mutual and other funds. Further, the company provides corporate and purchasing card, and corporate trust services; and merchant processing services, as well as offers cash and investment management, ATM processing, mortgage banking, and brokerage and leasing services. It serves individuals, businesses, institutional organizations, governmental entities, and other financial institutions. The company offers its services through a network of 3,133 banking offices primarily in the Midwest and West regions of the United States; and a network of 4,936 ATMs, as well as through on-line services and over mobile devices. U.S. Bancorp was founded in 1863 and is headquartered in Minneapolis, Minnesota.

 

3 Stocks in Focus: Baxter International Inc. (BAX), Level 3 Communications, Inc. (LVLT), Gilead Sciences Inc. (GILD)

Baxter International Inc. (BAX) climbed 2.15% during last trading as the stock added $1.01 to finish the day at $47.91 with about 6.33M shares changing hands, compared to its three month average trading volume of 3.62M. The $26.06B market cap company, which fluctuated between $46.68 and $48.08 during the day, currently situated 36.38% above its 52 week low of $35.54 and -4.21% away from its one year high of $50.16. The RSI of 72.18 indicates the stock is overbought at the current levels, sell for now.

Baxter International Inc. provides a portfolio of renal and hospital products. Its Renal segment provides products and services to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis (HD), home HD, continuous renal replacement therapy, and additional dialysis services. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and by patients at home under physician supervision. Baxter International Inc. offers its products through direct sales force, independent distributors or sales agents, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. The company was founded in 1931 and is headquartered in Deerfield, Illinois.

Level 3 Communications, Inc. (LVLT) gained $0.13 to close the day at a new closing price of $59.46, a 0.22% increase in value from its previous closing price that moved the stock 42.49% above its 52 week low of $41.73. A total of 1.95M shares exchanged hands during the day compared with its three month average trading volume of 3.6M. The stock, which fluctuated between $59.03 and $59.7 during the day, currently situated -0.64% below its 52 week high. The stock is up by 4.63% in the past one month and up by 10.01% over the past three months. With a one year target estimate of $63 and RSI of 65.66, the stock still has upside potential, making it a hold for now.

Level 3 Communications, Inc., together with its subsidiaries, operates as a facilities-based provider of a range of integrated communications services. It operates through North America, EMEA, and Latin America segments. The company offers Internet protocol (IP) and data services comprising Internet services, virtual private network, Ethernet, content delivery network, media delivery, Vyvx broadcast, managed, cloud and IT, and cloud connect services, as well as Communications as a Service. It also provides transport and fiber services comprising wavelengths, private lines, transoceanic services, and dark fiber, as well as related professional services; local and enterprise voice services, including Voice over Internet Protocol services and traditional circuit-switch based services; collaboration services, such as audio, Web, and video collaboration services; colocation and data center services comprising cloud, hosting, and application management solutions; and security services for mobile users or remote offices, governance, risk management, and compliance. In addition, the company provides wholesale voice services, including voice termination and toll free services. It primarily serves various types of customers, such as enterprises, content, government, and wholesale. The company was founded in 1884 and is headquartered in Broomfield, Colorado.

Gilead Sciences Inc. (GILD) had a light trading with around 10.36M shares changing hands compared to its three month average trading volume of 9.83M. The stock traded between $70.99 and $72.58 before closing at the price of $72.45 with 1.31% change on the day. The Foster City California 94404 based company is currently trading 3.83% above its 52 week low of $69.78 and -28.45% below its 52 week high of $103.1. Both the RSI indicator and target price of 49.57 and $93.71 respectively, lead us to believe that it should be put on hold over the coming weeks.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Traders Watch list: Abbott Laboratories (ABT), Gilead Sciences Inc. (GILD), Halliburton Company (HAL)

Abbott Laboratories (ABT) saw its value increase by 0.1% as the stock gained $0.04 to finish the day at a closing price of $41. The stock was lighter in trading and has fluctuated between $36.02-$45.79 per share for the past year. The shares, which traded within a range of $40.9 to $41.31 during the day, are up by 3.27% in the past three months and down by -6.58% over the past six months. It is currently trading 2.4% above its 20 day moving average and 4.74% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $46.85 a share over the next twelve months. The current relative strength index (RSI) reading is 67.23.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Gilead Sciences Inc. (GILD) shares were up in last trading by 0.06% to $71.26. It experienced lighter than average volume on day. The stock increased in value by almost 0.35% over the past week and fell -3.35% in the past month. It is currently trading -3.12% below its 50 day moving average and -10.22% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -29.62% decrease in value from its one year high of $103.1. The RSI indicator value of 41.6, lead us to believe that it is a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Halliburton Company (HAL) traded within a range of $57.75 to $58.47 after opening the day at $57.94. The company has seen its stock increase in value by 7.62% so far this year. The stock was up close to 0.26% on light volume in last trading session and closed at $58.21 per share. After the recent gain, the stock is currently holding -0.97% below its 52 week high of $58.78 and 111.81% above its 12-month low of $27.96. The shares are up by over 22.65% in the last three months, and the RSI indicator value of 67.4 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company’s Completion and Production segment offers production enhancement services, including stimulation and sand control services; and cementing services, such as bonding the well, well casing, and casing equipment. It also provides completion tools that offer downhole solutions and services, including well completion products and services, intelligent well completions, liner hanger systems, sand control systems, and service tools; pressure control services comprising coiled tubing, hydraulic workover units, and downhole tools; and pipeline and process services, such as pre-commissioning and maintenance, subsea pipeline, conventional pipeline, and process services. In addition, this segment offers oilfield production and completion chemicals and services; electrical submersible pumps and progressive cavity pumps; and installation, maintenance, repair, and testing services. The company’s Drilling and Evaluation segment provides drilling fluid systems, performance additives, completion fluids, solids control, specialized testing equipment, and waste management services; and drilling systems and services. It also offers wireline and perforating services that include open-hole logging, cased-hole and slickline, borehole seismic, and formation and reservoir solutions; and drill bits and services comprising roller cone rock bits, fixed cutter bits, hole enlargement, and related downhole tools and services, as well as coring equipment and services. In addition, this segment offers integrated exploration, drilling, and production software, as well as related professional and data management services; testing and subsea services, such as acquisition and analysis of reservoir information and optimization solutions; and oilfield project management and integrated solutions. Halliburton Company was founded in 1919 and is based in Houston, Texas.

 

Stocks To Track: Gilead Sciences Inc. (GILD), Morgan Stanley (MS), Merck & Co., Inc. (MRK)

Gilead Sciences Inc. (GILD) climbed 2.36% during last trading as the stock added $1.66 to finish the day at $71.91 with about 14.03M shares changing hands, compared to its three month average trading volume of 9.84M. The $95.49B market cap company, which fluctuated between $70.72 and $72.34 during the day, currently situated 3.05% above its 52 week low of $69.78 and -28.98% away from its one year high of $103.1. The RSI of 43.68 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Morgan Stanley (MS) gained $1.13 to close the day at a new closing price of $43.86, a 2.64% increase in value from its previous closing price that moved the stock 111.11% above its 52 week low of $21.16. A total of 13.92M shares exchanged hands during the day compared with its three month average trading volume of 12.25M. The stock, which fluctuated between $42.96 and $43.9 during the day, currently situated -1.66% below its 52 week high. The stock is up by 2.5% in the past one month and up by 32.18% over the past three months. With a one year target estimate of $46.37 and RSI of 57.73, the stock still has upside potential, making it a hold for now.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The company’s Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; and corporate lending services, credit products, and investments and research services. Its Wealth Management segment offers various financial services and solutions covering brokerage and investment advisory services, market-making services in fixed income securities, financial and wealth planning services, annuity and insurance products, credit and other lending products, and banking and retirement plan services to individual investors, small-to-medium sized businesses, and institutions. The company’s Investment Management segment provides various investment strategies and products comprising asset management, including equity, fixed income, liquidity, alternatives, and managed futures products. This segment is also involved in merchant banking and real estate investing businesses. Morgan Stanley was founded in 1924 and is headquartered in New York, New York.

Merck & Co., Inc. (MRK) had a active trading with around 13.74M shares changing hands compared to its three month average trading volume of 11.53M. The stock traded between $60.76 and $61.38 before closing at the price of $61.08 with -0.21% change on the day. The Kenilworth New Jersey 07033 based company is currently trading 31.44% above its 52 week low of $47.97 and -5.98% below its 52 week high of $65.46. Both the RSI indicator and target price of 50.44 and $68.21 respectively, lead us to believe that it should be put on hold over the coming weeks.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

 

Stocks Alert: The Williams Companies, Inc. (WMB), Gilead Sciences Inc. (GILD), Halliburton Company (HAL)

The Williams Companies, Inc. (WMB) grew with the stock adding 0.96% or $0.27 to close at $28.48 on light trading volume of 10.93M compared its three months average trading volume of 9.05M. The Tulsa Oklahoma 74172 based company operating under the Oil & Gas Pipelines industry has been trending up for the last 52 weeks, with the shares price now 68.4% up for the period and down by -8.54% so far this year. With price target of $32.14 and a 201.7% rebound from 52-week low, The Williams Companies, Inc. has plenty of upside potential, making it a hold with a view buy.

The Williams Companies, Inc. operates as an energy infrastructure company primarily in the United States. The company operates through Williams Partners, Williams NGL (natural gas liquids) & Petchem Services, and Other segments. It owns and operates natural gas pipeline system extending from Texas, Louisiana, Mississippi, and the offshore Gulf of Mexico through Alabama, Georgia, South Carolina, North Carolina, Virginia, Maryland, Delaware, Pennsylvania, and New Jersey to the New York City metropolitan area. The company also owns and operates a natural gas pipeline system extending from the San Juan basin in northwestern New Mexico and southwestern Colorado through Colorado, Utah, Wyoming, Idaho, Oregon, and Washington to a point on the Canadian border near Sumas, Washington; gulfstream natural gas pipeline system extending from the Mobile Bay area in Alabama to markets in Florida; and constitution pipeline that would connect its gathering system in Susquehanna County, Pennsylvania to the Iroquois Gas Transmission and Tennessee Gas Pipeline systems in New York. In addition, it provides natural gas gathering, treating, processing, and compression; NGL production, fractionation, storage, marketing, and transportation; deepwater production handling and crude oil transportation; and olefin production services, as well as transports and stores natural gas to local natural gas distribution companies, municipal utilities, direct industrial users, electric power generators, and natural gas marketers and producers. Further, the company extracts, fractionates, treats, stores, and sells ethane/ethylene, propane, propylene, normal butane, isobutene, alky feedstock, and condensate. Additionally, it provides construction management services for third parties. As of December 31, 2015, the company owned and operated approximately 13,600 miles of pipelines. The Williams Companies, Inc. was founded in 1908 and is headquartered in Tulsa, Oklahoma.

#VALUE!

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Halliburton Company (HAL) shares were up in last trading by 3.32% to $56.62. It experienced higher than average volume on day. The stock increased in value by almost 2.93% over the past week and grew 3.02% in the past month. It is currently trading 6.85% above its 50 day moving average and 24.17% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -0.63% decrease in value from its one year high of $56.98. The RSI indicator value of 60.62, lead us to believe that it is a hold for now.

Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company’s Completion and Production segment offers production enhancement services, including stimulation and sand control services; and cementing services, such as bonding the well, well casing, and casing equipment. It also provides completion tools that offer downhole solutions and services, including well completion products and services, intelligent well completions, liner hanger systems, sand control systems, and service tools; pressure control services comprising coiled tubing, hydraulic workover units, and downhole tools; and pipeline and process services, such as pre-commissioning and maintenance, subsea pipeline, conventional pipeline, and process services. In addition, this segment offers oilfield production and completion chemicals and services; electrical submersible pumps and progressive cavity pumps; and installation, maintenance, repair, and testing services. The company’s Drilling and Evaluation segment provides drilling fluid systems, performance additives, completion fluids, solids control, specialized testing equipment, and waste management services; and drilling systems and services. It also offers wireline and perforating services that include open-hole logging, cased-hole and slickline, borehole seismic, and formation and reservoir solutions; and drill bits and services comprising roller cone rock bits, fixed cutter bits, hole enlargement, and related downhole tools and services, as well as coring equipment and services. In addition, this segment offers integrated exploration, drilling, and production software, as well as related professional and data management services; testing and subsea services, such as acquisition and analysis of reservoir information and optimization solutions; and oilfield project management and integrated solutions. Halliburton Company was founded in 1919 and is based in Houston, Texas.